Operations begin at new Genezen lentiviral and retroviral vector lab in Indianapolis

By Jane Byrne contact

- Last updated on GMT

Ribbon cutting ceremony for new lab © Genezen
Ribbon cutting ceremony for new lab © Genezen

Related tags: lentiviral vector, retroviral, Cell lines, upstream, cell and gene therapy

Genezen, a cell and gene therapy focused CDMO, has just opened a new process development and analytical lab, a build that represents the first phase of a 75,000+ square foot cGMP-compliant lentiviral and retroviral vector production facility in Indianapolis.

The next phase, with cGMP production suites, is currently underway and due to complete in early 2022.

The lab, said the CDMO, will deliver a full suite of process development capabilities to support cGMP and commercial readiness, upstream and downstream process improvements, research grade and preclinical vector production, and analytical assay development and validation from the site.

In June, Genezen told us the cell and gene therapy sector is evolving rapidly, and there is growing demand for capacity and expertise. “We are investing heavily to meet this need now and in the future.”

Academic partnerships 

The CDMO started out by teaming up with academic vector production facilities to utilize their excess production capacity, and will continue to provide cell manufacturing and patient sample testing through such alliances. “We are now expanding into a stand-alone facility while continuing our academic partnerships.”

The new facility, which will have a global focus in terms of target clients, is being funded by a majority investment from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector.

Cell expansion, banking

Once finished, the site will deliver aseptic manufacturing of lentiviral and retroviral vectors from multiple cGMP production suites and will offer capabilities for host cell expansion, host cell banking, and viral vector production via transient transfection and producer cell lines.

Analytical testing services, including recombinant competent lentivirus (RCL) testing, vector stability testing, and safety and sterility testing, will also be available.

In terms of capacity for viral vector production when the facility is fully operational, the company told us previously: “Capacity is difficult to define because of the variability between client vectors and the production platform the client chooses to use, but we will be continuing to grow with our client's needs.” 

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers